Anticorps Polyclonal de lapin anti-PCSK9

• Phare
• Validé par KD/KO

PCSK9 Polyclonal Antibody for IHC, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat et plus (1)

Applications

WB, IP, IHC, IF, ChIP, ELISA

Conjugaison

Non conjugué

Publications

39

Avis (1)

N° de cat : 55206-1-AP

Synonymes

FH3, HCHOLA3, LDLCQ1, NARC 1, NARC1, PC9, PCSK9, Proprotein convertase 9

---

Galerie de données de validation

• 

  WB analysis using 55206-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 55206-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: cellules COLO 320, cellules HepG2, cellules SMMC-7721
• Résultats positifs en IHC: tissu de cancer du côlon humain, ; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:3000
• Immunohistochimie (IHC): IHC : 1:250-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 7 publications below
• WB: See 33 publications below
• IHC: See 13 publications below
• IF: See 4 publications below
• IP: See 1 publications below
• ChIP: See 1 publications below

Informations sur le produit

55206-1-AP cible PCSK9 dans les applications de WB, IP, IHC, IF, ChIP, ELISA et montre une réactivité avec des échantillons Humain, rat

• Réactivité: Humain, rat
• Réactivité citée: rat, Humain, Hamster
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Peptide
• Nom complet: proprotein convertase subtilisin/kexin type 9
• Masse moléculaire calculée: 74 kDa
• Poids moléculaire observé: 58-62 kDa, 72-78 kDa
• Numéro d’acquisition GenBank: NM_174936
• Symbole du gène: PCSK9
• Identification du gène (NCBI): 255738
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)

Publications

Species	Application	Title
human	WB	Nature; Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.; Authors - Xinjian Liu ; KO Validated
	WB,IHC,IF	J Nanobiotechnology; Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy; Authors - Zhenxian Li
human,hamster	WB	Biomed Pharmacother; Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases; Authors - Hui-Hui Guo
human	IHC	Front Immunol; PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer; Authors - Xiang Gao
human	WB	Int J Mol Sci; Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity; Authors - Po-Wei Chen
rat,human	WB,IHC,IF	Int J Mol Sci; Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells.; Authors - Chiara Barisione

Avis

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.

---

FH

Malak (Verified Customer) (11-30-2020)

The antibody works very well in IHC staining especially at pH6 and 1/100 dilution

• Applications: Immunohistochemistry
• Primary Antibody Dilution: 1/100
• Cell Tissue Type: Hepatic tissue